Leukemia Stages

Acute lymphocytic leukemia (ALL) does not have clearly defined stages, such as early or late stages. Instead, it is classified by factors like the type of affected lymphocyte (B cell or T cell) and specific genetic mutations. ALL is broadly described based on treatment phases: untreated, in remission, or relapsed.

Acute myeloid leukemia (AML) doesn't follow a traditional stage-based classification but instead is categorized according to its progression and specific genetic characteristics. Physicians classify AML based on factors like the type of myeloid cell affected, genetic mutations present in the leukemia cells, and whether it is a new case or a relapse.

Acute promyelocytic leukemia (APL) does not use a traditional staging system like other cancers. Instead, the disease is described based on disease progression and response to treatment.

B-cell leukemia is an aggressive type of leukemia with no defined stages. It is characterized by a high number of prolymphocytes in the blood.

Chronic lymphocytic leukemia (CLL) is one of few leukemias that use a defined staging system, called the Rai system. There are also other systems used to stage CLL.

The Rai system categorizes CLL into five stages:

• Stage 0: This early stage of leukemia is marked by high white blood cell counts without significant symptoms. Patients may not need treatment right away, as the disease progresses slowly.
• Stage I (1): Involves swollen lymph nodes but no signs of low red blood cell count (anemia) or low platelet count (thrombocytopenia).
• Stage II (2): This stage is characterized by an enlarged spleen or liver in addition to swollen lymph nodes.
• Stage III (3): Indicates anemia due to leukemia cells crowding the bone marrow.
• Stage IV (4): This stage involves low platelet counts, which increase the risk of bleeding.

The Binet system is a simple way to classify CLL into three stages based on blood test results and the number of swollen lymph nodes or other lymphatic areas.

• Stage A: No anemia (low red blood cells) or low platelets. Fewer than three enlarged lymph node areas.
• Stage B: No anemia or low platelets, but three or more enlarged lymph node areas.
• Stage C: Anemia or low platelets, regardless of the number of enlarged lymph node areas.

The CLL-IPI system uses key factors to predict how aggressive CLL is and guide treatment decisions. These factors include:

• Genetic changes: Mutations in the TP53 gene or unmutated IGHV gene.
• Blood marker: High beta-2 microglobulin levels (a protein linked to disease activity).
• Disease stage: Advanced stages (Binet B-C or Rai IV).
• Age: Over 65 years.

Patients are grouped into four risk categories based on a points system:

• Low risk (0-1 points): No treatment needed.
• Intermediate risk (2-3 points): Only treat if symptoms are severe.
• High risk (4-6 points): Treatment is usually recommended unless no symptoms.
• Very high risk (7-10 points): Consider newer treatments or clinical trials rather than traditional chemotherapy.

Chronic myeloid leukemia (CML) progresses through three phases rather than stages.

• Chronic phase: This beginning stage of leukemia often presents with few symptoms, and many patients may not feel sick. Blood tests show elevated white blood cell counts. Treatment with tyrosine kinase inhibitors (TKIs) typically keeps the disease under control for long periods.
• Accelerated phase: In this phase, the disease progresses more rapidly, and blood counts become more difficult to control.
• Blast crisis phase: This phase is similar to acute leukemia and represents the final stages of leukemia, where there is an overwhelming presence of immature leukemia cells, or blasts. This phase requires aggressive treatment.

Chronic myelomonocytic leukemia (CMML) is classified into these categories:

• CMML-0: Very low levels of immature cells (blasts) are present in the bone marrow and blood.
• CMML-1: Few immature cells are present in the bone marrow and blood.
• CMML-2: A higher number of blasts is present, indicating more advanced disease and a higher risk of progression to acute myeloid leukemia.

Hairy cell leukemia (HCL) is classified based on the response to treatment, with physicians describing it as either active or in remission.

Large granular lymphocytic leukemia (LGL) lacks a specific staging system due to its gradual progression. Instead, the disease is assessed based on the number of abnormal lymphocytes, the presence of symptoms, and its impact on organ function, particularly the bone marrow, spleen, and liver. It can be indolent (meaning it progresses slowly with minimal symptoms) or aggressive, which requires prompt treatment.

Plasma cell leukemia (PCL) is a rare and aggressive subtype of multiple myeloma that is assessed based on levels of circulating plasma cells.

T-cell leukemia does not have defined stages but is categorized based on symptoms and blood cell counts.